Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. SGS AG
  6. News
  7. Summary
    SGSN   CH0002497458

SGS AG

(SGSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SGS : Are Biosimilars Yet to Fulfill Their True Potential?

07/22/2021 | 02:08am EDT
On the face of it, biosimilars have the potential to reinvent the healthcare industry, making sought after medicines both cheaper and more accessible when locally produced.

Figures have even estimated that biosimilars might be able to save the global healthcare industry around USD 160 BN between 2019 and 2023.

However, as things stand, biosimilars are not having as widespread an impact as possible. This article examines why, digging into three key analytical challenges that are thus far inhibiting Biosimilars production across the world.

Read the full article

Learn More About the Author

Luc-Alain Savoy, Global Head of Biologics at SGS, who has recently been added to the list of top 100 most influential people in the biopharmaceutical industry, has been working for SGS for over 32 years.

For more information, please contact:

Aurelia Resines
Global Head of Marketing
t: +41 22 739 91 11

Disclaimer

SGS SA published this content on 22 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 July 2021 06:07:10 UTC.


ę Publicnow 2021
All news about SGS AG
03:32aSGS : Oregon, USA, Issues Temporary Administrative Order to Clarify Reporting Requirements..
PU
02:12aSGS : Celebrates 80 Years of Delivering Renowned Metallurgy to the Global Mining Industry
PU
02:12aSGS : Detecting & Preventing Coffee Fraud
PU
12:12aSGS : Signs Grain & Feed Trade Association's Sustainability Pledge
MT
09/23SGS : Committing to a Sustainable Future by Becoming a Member of the Gafta Sustainability ..
PU
09/23SGS : Germany's BfR Issues Guidelines for Natural and Synthetic Rubber Commodities
PU
09/23SGS : EU – ECHA Launches Second 2021 SVHC Consultation on Four Proposals
PU
09/21SGS : U.S. California Prop 65 60-Day Notices on Bisphenol-A (BPA) in Socks
PU
09/20TOY UPDATES : September 2021
PU
09/17SGS : The Ongoing Issue of Asbestos on Ships
PU
More news
Analyst Recommendations on SGS AG
More recommendations
Financials
Sales 2021 6 330 M 6 842 M 6 842 M
Net income 2021 642 M 694 M 694 M
Net Debt 2021 1 934 M 2 091 M 2 091 M
P/E ratio 2021 33,4x
Yield 2021 2,86%
Capitalization 21 586 M 23 326 M 23 331 M
EV / Sales 2021 3,72x
EV / Sales 2022 3,51x
Nbr of Employees 92 143
Free-Float 79,7%
Chart SGS AG
Duration : Period :
SGS AG Technical Analysis Chart | SGSN | CH0002497458 | MarketScreener
Technical analysis trends SGS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Last Close Price 2 880,00 CHF
Average target price 2 856,47 CHF
Spread / Average Target -0,82%
EPS Revisions
Managers and Directors
Frankie Ng Chief Executive Officer
Dominik de Daniel Chief Financial Officer
Calvin Grieder Chairman
Olivier Merkt Chief Compliance Officer & SVP-Legal
August Franšois von Finck Independent Director